Literature DB >> 21764510

Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors.

Shikha Gaur1, Linling Chen, Lixin Yang, Xiwei Wu, Frank Un, Yun Yen.   

Abstract

The present study was performed to investigate the possible role of mTOR inhibitors in restoring chemosensitivity to adriamycin/cisplatin and elucidate the underlying mechanism. Combining adriamycin/cisplatin with torisel synergistically inhibited the cell proliferation in human oropharyngeal carcinoma cell line KB and its multidrug-resistant subclone KB/7D. Combining adriamycin and torisel inhibited the phosphorylation of 4EBP-1 and p70S6K, the proteins involved in mTOR pathway, increased expression of γH2AX indicative of DNA damage, triggered cell cycle arrest at G2/M and apoptosis. We conclude that chromatin decondensation by DNA damage provided an easy access for torisel to block the translation of proteins essential for DNA repair thereby restoring the chemosensitivity.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21764510     DOI: 10.1016/j.canlet.2011.06.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.

Authors:  Shikha Gaur; Mitchell E Gross; Chun-Peng Liao; Bin Qian; Jean C Shih
Journal:  Prostate       Date:  2019-01-28       Impact factor: 4.104

2.  Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.

Authors:  Jun He; Jing-Jie Yu; Qing Xu; Lin Wang; Jenny Z Zheng; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

3.  Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks.

Authors:  Changxian Shen; Duane Oswald; Doris Phelps; Hakan Cam; Christopher E Pelloski; Qishen Pang; Peter J Houghton
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

4.  mTOR inhibitors: A novel class of anti-cancer agents.

Authors:  Haris Riaz; Talha Riaz; Syed A Hussain
Journal:  Infect Agent Cancer       Date:  2012-01-03       Impact factor: 2.965

5.  Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.

Authors:  Adriana Blancafort; Ariadna Giró-Perafita; Glòria Oliveras; Sònia Palomeras; Carlos Turrado; Òscar Campuzano; Dolors Carrión-Salip; Anna Massaguer; Ramon Brugada; Marta Palafox; Jorge Gómez-Miragaya; Eva González-Suárez; Teresa Puig
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

6.  Reciprocal regulation of autophagy and dNTP pools in human cancer cells.

Authors:  Wei Chen; Lisheng Zhang; Keqiang Zhang; Bingsen Zhou; Mei-Ling Kuo; Shuya Hu; Linling Chen; Michelle Tang; Yun-Ru Chen; Lixin Yang; David K Ann; Yun Yen
Journal:  Autophagy       Date:  2014-05-16       Impact factor: 16.016

7.  mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer.

Authors:  Wei Gao; John Zeng Hong Li; Jimmy Yu Wai Chan; Wai Kuen Ho; Thian-Sze Wong
Journal:  ISRN Otolaryngol       Date:  2012-10-18

8.  C. elegans AMPKs promote survival and arrest germline development during nutrient stress.

Authors:  Masamitsu Fukuyama; Kensuke Sakuma; Riyong Park; Hidefumi Kasuga; Ryotaro Nagaya; Yuriko Atsumi; Yumi Shimomura; Shinya Takahashi; Hiroaki Kajiho; Ann Rougvie; Kenji Kontani; Toshiaki Katada
Journal:  Biol Open       Date:  2012-08-02       Impact factor: 2.422

9.  MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.

Authors:  Shaohua Xu; Guang-Bo Fu; Zhen Tao; Jun OuYang; Fanfei Kong; Bing-Hua Jiang; Xiaoping Wan; Ke Chen
Journal:  Oncotarget       Date:  2015-09-22

10.  Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.

Authors:  Shikha Gaur; Linling Chen; Vincent Ann; Wei-Chen Lin; Yafan Wang; Vincent H S Chang; Nan Yong Hsu; Her-Shuyong Shia; Yun Yen
Journal:  Mol Cancer       Date:  2014-02-04       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.